Shufeng Jiedu Granule against mild COVID-19: Protocol of the randomized, double-blind, placebo-controlled, multi-center heal-COVID phase III study
The global risk assessment remains high due to the ongoing virulence of SARS-CoV-2 Omicron sub-lineages. This Phase III study adopts a robust methodology to investigate SFJDG as a treatment for mild COVID-19 as well as it's effectiveness and safety. Furthermore, this study aim to provide sufficient scientific evidence for the market registration of SFJDG especially for home-treated patients. If successful, SFJDG could be a meaningful addition to therapeutic options for mild infections, supporting public health strategies in managing the ongoing impact of SARS-CoV-2.
Authors
- Hongzhou Lu (ORCID: https://orcid.org/0000-0003-3590-4790)
- Qiang Zhu (ORCID: https://orcid.org/0000-0002-5843-9724)
- Yang Li (ORCID: https://orcid.org/0000-0002-8239-3279)
- Yuanlong Lin
- Thomas Friedemann (ORCID: https://orcid.org/0000-0002-8792-9781)
- Jun Pan
- Xiangyu Li (ORCID: https://orcid.org/0000-0003-4650-5517)
- Qingsong Liu (ORCID: https://orcid.org/0000-0002-7829-2547)
- Sven Schröder
- Fuxiang Wang
Institutions
- Universität Hamburg (DE)
- Chinese Academy of Sciences (CN)
- Anhui University of Traditional Chinese Medicine (CN)
- Hefei Institutes of Physical Science (CN)
- Southern University of Science and Technology (CN)
- University Medical Center Hamburg-Eppendorf (DE)
- Shenzhen Second People's Hospital (CN)
- Shenzhen Third People’s Hospital (CN)
Publication Details
- Journal
- Chinese Herbal Medicines
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1016/j.chmed.2025.04.005
- Citations
- 1
- Primary Topic
- Pharmacological Effects of Natural Compounds
- Type
- article
- Field-Weighted Citation Impact
- 1.56